ID   HEK293-EBNA1-6E
SY   HEK 293EBNA1-6E; HEK293-6E; HEK2936E; 293-6E; 293FEt-clone 6E
DR   Wikidata; Q54882446
RX   Patent=US8551774;
RX   PubMed=21356792;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, IDA of Canada (IDAC); 150305-01.
CC   Characteristics: The use of recombinant protein expression vectors containing the EBV oriP in cell lines stably expressing EBV's EBNA1 protein significantly increases recombinant protein yield.
CC   Characteristics: This cell line is transfected with EBNA1t, a truncated version of EBV EBNA1 lacking the Gly-Gly-Ala repeats region. It has an enhanced ability to produce recombinant protein compared to HEK293-EBNA (CVCL_6974).
CC   Transfected with: UniProtKB; P03211; EBV EBNA1 (with del 101-324 = EBNA1t).
CC   Transformant: NCBI_TaxID; 28285; Adenovirus 5.
CC   Derived from sampling site: Fetal kidney.
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_6642 ! HEK293-F
SX   Female
AG   Fetus
CA   Transformed cell line
DT   Created: 01-12-16; Last updated: 23-09-21; Version: 7
RX   Patent=US8551774;
RA   Durocher Y.;
RT   "Expression vectors containing a truncated Epstein Barr nuclear
RT   antigen 1 lacking the Gly-Gly-Ala domain for enhanced transient gene
RT   expression.";
RL   Patent number US8551774, 08-Oct-2013.
RX   PubMed=21356792; DOI=10.1101/pdb.prot4976;
RA   Tom R., Bisson L., Durocher Y.;
RT   "Culture of HEK293-EBNA1 cells for production of recombinant
RT   proteins.";
RL   CSH Protoc. 2008:Pdb.prot4976-Pdb.prot4976(2008).